L.casei DG
Dietary Supplement(At least 24 billion live cells per capsule)
1 capsule, b.i.d. for 12 weeks
NCT Number: NCT03449628
To assess the effect of L. casei DG® (Lactobacillus paracasei CNCMI1572; Enterolactis® plus) on abdominal symptoms and gut microbiota metabolism/composition in non constipated patients with IBS (Irritable Bowel Syndrome). Patients will be randomized to receive L. casei DG® capsules, b.i.d. for 12 weeks the a 4 weeks Follow Up period will follow.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
A.O. Bolognini, Seriate, BG, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
(At least 24 billion live cells per capsule)
1 capsule, b.i.d. for 12 weeks
1 capsule, b.i.d. for 12 weeks
Time frame: 12 weeks
Patients who record on ≥ 50% of the days a reduction of ≥ 30% from their average baseline score for their worst abdominal pain.The standard 11-point numeric rating scale (from 0=none to 10=worst possible pain) will be used to measure abdominal pain.
Time frame: 12 weeks
Patients who record a stool-consistency score < 5 in the same days in which they record a reduction of ≥ 30% from their average baseline score for their worst abdominal pain .For abnormal defecation, stool frequency and form will be measured using the Bristol Stool Form Scale (BSFS).
Time frame: 16 weeks
reduction of ≥ 30% from baseline in the score for the worst abdominal pain on ≥ 50% of days
Time frame: 16 weeks
Improvement in the global symptom score: a score of 0 or 1, or an improvement ≥ 2 over the baseline score, on ≥ 50% of days
Time frame: 16 weeks
Adequate relief of IBS symptoms on ≥ 50% of the past weeks (a response of "yes" on ≥50% of the weeks to the following question: "Over the past week, have you had adequate relief of your IBS symptoms?)"
Time frame: 16 weeks
To assess the severity of symptoms related to Irritable Bowel Syndrome, assessed at baseline and at the end of treatment after 12 weeks (it is considered clinically significant a score reduction of at least 50 points). The questionnaire is composed by five questions wich generate a maximum score of 100 each using prompted visual analogue scales, leading to a total possible score of 500.
Time frame: 16 weeks
stool consistency score ≤ 5 assessed with BSFS (Bristol Stool Form Scale) BSFS evaluates stool form and consistency (score from 1=dry stool to 7=liquid stoo. The ideal stool is generally 3 or 4)
Time frame: 16 weeks
Overall satisfaction with treatment assessed by VAS scale (Visual Analogue Scale)
Time frame: 16 weeks
Quality of life assessment by validated Short-Form 12 Items Health Survey (SF-12) on a scale of 0 to 100
Time frame: 16 weeks
type and frequencies of rescue medication
Time frame: 16 weeks
Evaluation of changes in the gut microbiota composition and the relative abundance of bacterial OTUs (Operational Taxonomic Unit).
Time frame: 16 weeks
Evaluation of Short Chain Fatty Acids levels in fecal samples
Time frame: 16 weeks
Evaluation of Free aminoacids levels in fecal samples
Time frame: 16 weeks
Evaluation of biogenic amines levels in fecal samples
Time frame: 16 weeks
evaluation of serum levels of zonulin
Time frame: 16 weeks
evaluation of serum levels of citrulline
Time frame: 16 weeks
evaluation of serum levels of PV-1 (Plasmalemma vesicle-associated) protein
Time frame: 16 weeks
the recovery of L. casei DG® strain in the feces
SOFAR S.p.A.
Industry
L. Casei DG® (Lactobacillus Paracasei CNCMI1572) in the Treatment of Patients With Irritable Bowel Syndrome: a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study.
Acronym: PROBE2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07089420
Colitis, Colitis, Ulcerative
Salem, New Hampshire, United States
View Trial DetailsNCT05995899
Colonic Diseases, Colonic Diseases, Functional
Boston, Massachusetts, United States
View Trial DetailsNCT06297785
Colonic Diseases, Colonic Diseases, Functional
Gothenburg, Sweden
View Trial DetailsNCT06687616
Colonic Diseases, Colonic Diseases, Functional
Los Angeles, California, United States
View Trial Details